These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36697937)

  • 1. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults.
    Chen G; Li N; Dai X; Tu S; Shen Z; Wu K; Jin T; Wu J; Peng C; Sheng G; Zhu M; Tang L; Li L
    Infect Dis Ther; 2023 Feb; 12(2):663-675. PubMed ID: 36697937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, pharmacokinetics, and immunogenicity of JMB2002-an antibody against COVID-19: a phase 1 clinical trial in healthy Chinese adults.
    Chen G; Zhang Y; Wu K; Jin T; Peng C; Jiang Q; Tian W; Chen Z; Shen Z; Sheng G
    BMC Infect Dis; 2023 Jun; 23(1):437. PubMed ID: 37370000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study.
    Li S; Wu X; Li N; Cao G; Wang J; Chen Y; Li S; He J; Wu J; Yang H; Lin K; Qiu C; Liu A; Zhou H; Adrian F; Schweizer L; Zhang W; Gu J; Zhang J
    Front Pharmacol; 2023; 14():1117293. PubMed ID: 37332355
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study).
    Bauer M; Weyland A; Marx G; Bloos F; Weber S; Weiler N; Kluge S; Diers A; Simon TP; Lautenschläger I; Gründling M; Jaschinski U; Simon P; Nierhaus A; Moerer O; Reill L; Jörres A; Guo R; Loeffler M; Reinhart K; Riedemann N
    Crit Care Explor; 2021 Nov; 3(11):e0577. PubMed ID: 34806021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability and pharmacokinetics of WXFL10203614 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase Ⅰ study.
    Huang K; Ding Y; Que L; Chu N; Shi Y; Qian Z; Qin W; Chen Y; Gu X; Wang J; Zhang Z; Xu J; He Q
    Front Pharmacol; 2022; 13():1057949. PubMed ID: 36408263
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized dose-escalation study on the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of a novel recombinant human albumin in healthy subjects.
    Li C; Xiang W; Wu M; Zhang H; Cheng J; Yang T; Mai J; Chi X; Gao X; Ding Y; Niu J
    Eur J Pharm Sci; 2021 Oct; 165():105923. PubMed ID: 34229078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers.
    Wu M; Zhang H; Li Q; Chen H; Fang M; Yang L; Ding Y
    Front Pharmacol; 2021; 12():794054. PubMed ID: 35310892
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
    Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
    Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective Autotaxin inhibitor, in healthy subjects: A phase I randomized placebo-controlled trial.
    Yang L; Shu P; Wu N; Hu M; Luo Z
    Eur J Pharm Sci; 2023 Oct; 189():106552. PubMed ID: 37532064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
    Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
    Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study.
    Zhao X; Liu H; Tian W; Fang L; Yu M; Wu X; Liu A; Wan R; Li L; Luo J; Li Y; Liu B; He Y; Chen X; Li Y; Xu D; Wang H; Han X
    Front Pharmacol; 2023; 14():1227470. PubMed ID: 37680714
    [No Abstract]   [Full Text] [Related]  

  • 13. First-in-Human, Double-Blind, Randomized, Placebo-Controlled Trial of TQ-F3083, a New Dipeptidyl Peptidase-4 Inhibitor, in Healthy Chinese Adults.
    Liu J; Zhu X; Zhang H; Wei H; Yang D; Xu Z; Huo D; Li X; Ding Y
    Front Pharmacol; 2021; 12():689523. PubMed ID: 34366847
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.
    Shu YJ; He JF; Pei RJ; He P; Huang ZH; Chen SM; Ou ZQ; Deng JL; Zeng PY; Zhou J; Min YQ; Deng F; Peng H; Zhang Z; Wang B; Xu ZH; Guan WX; Hu ZY; Zhang JK
    Chin Med J (Engl); 2021 Jul; 134(16):1967-1976. PubMed ID: 34310400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
    Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
    Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerance, and pharmacokinetics of salvianolic acid B in healthy Chinese volunteers: A randomized, double-blind, placebo-controlled phase 1 clinical trial.
    Cheng J; Long J; Zhang J; Han L; Hu Y; Liu J; Qiu R; Zhu Z; Fan H
    Front Pharmacol; 2023; 14():1146309. PubMed ID: 37124221
    [No Abstract]   [Full Text] [Related]  

  • 19. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral AL01211 in Healthy Chinese Volunteers.
    Dong L; Xiang J; Babcock M; Cheng Y; Wang Y; Shen Y; Li L; Tan L; Garovoy M; Hu W; Zheng J
    Clin Drug Investig; 2024 Jun; 44(6):387-398. PubMed ID: 38698285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.